Opendata, web and dolomites

LIPOBITS SIGNED

Liposome-based Biomimetic Treatment for auto-immune diabetes (T1D)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LIPOBITS project word cloud

Explore the words cloud of the LIPOBITS project. It provides you a very rough idea of what is the project "LIPOBITS" about.

onset    discover    insulin    considering    global    lower    treatment    reaction    containing    300    glycaemic    foreseen    liposomes    action    network    diabetes    solution    immune    stopping    systemic    enlarging    producing    complementary    encapsulation    treatments    platform    strategy    preclinical    secondary    competitors    diseases    asset    tolerance    marketed    models    despite    administration    assays    10    ahead    antigen    proprietary    regulatory    toxicity    animal    preventive    therapies    physiologic    induce    t1d    competitive    immunosuppressive    total    detected    ad    life    permanent    validated    deeper    prevent    exogenous    reverse    none    recover    dimension    advantages    incidence    society    2022    lt    jobs    auto    therapeutic    mechanism    continuous    chronic    licensees    sustained    scaling    therapeutics    lasting    population    innovation    lipobits    mainly    cycle    ing    steady    market    innovative    autoantigens    cells    feasibility    qualified    acute    liposome    worldwide    incomes    start    vaccine    cure    autoimmune    ipr    effect    insulins    solid    disease    biomimetic    palliative    quality    beta    generate    roadmap    company   

Project "LIPOBITS" data sheet

The following table provides information about the project.

Coordinator
AHEAD THERAPEUTICS SL 

Organization address
address: EDIFICI EUREKA PARC RECERCA UAB CAMPUS UAB S/N
city: CERDANYOLA DEL VALLES
postcode: 8193
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.aheadtherapeutics.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AHEAD THERAPEUTICS SL ES (CERDANYOLA DEL VALLES) coordinator 50˙000.00

Map

 Project objective

Autoimmune diseases (AD) affect 5-10% of the global population and require chronic palliative treatments, resulting in lower quality of life and great costs for society. Moreover, a steady rise in the incidence of some AD such as Type 1 diabetes (T1D) has been detected worldwide. Main treatments for T1D are currently based on the continuous administration of exogenous insulin, but none of the 20 existing marketed insulins can achieve a sustained glycaemic level control. Thus, they cannot fully prevent T1D’s long term and acute side effects.

Ahead Therapeutics is a start-up company exploiting a proprietary encapsulation technology to develop treatments for different AD. It has developed an innovative solution for T1D based on the use of liposomes containing auto-autoantigens. Through a biomimetic process, these liposomes can induce antigen specific immune tolerance, stopping the autoimmune reaction and allowing insulin-producing β-cells to recover. Despite its potential for preventive use, Ahead’s treatment is mainly foreseen as a therapeutic reverse vaccine on the onset of T1D, leading to a permanent cure of the disease.

Ahead solution has several competitive advantages derived from its biomimetic/physiologic mechanism of action: long-lasting/permanent effect, non-systemic immunosuppressive, no secondary effects/toxicity, low-cost production, complementary with other therapies. The liposome-based platform has already been validated in animal models and preclinical non-regulatory assays are being completed. Current feasibility study will be now focus on defining a Regulatory Roadmap & IPR strategy, enlarging key partners network, discover new potential licensees, scaling up liposomes production and analyse deeper market & competitors.

LIPOBITS is a solid high-potential innovation project expected to support Ahead’s global dimension and to generate 7 high qualified jobs total incomes of 10,5 M€ by 2022, and < 300 M € considering the whole life cycle of the asset.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LIPOBITS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LIPOBITS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

LiCrete (2018)

LiCrete - Light transmitting composite material for building purposes

Read More